|
시장보고서
상품코드
2016815
디지털 정량 흡입기 시장 규모, 점유율, 동향 및 예측 : 유형, 제품 유형, 지역별(2026-2034년)Digital Dose Inhaler Market Size, Share, Trends and Forecast by Type, Product, and Region, 2026-2034 |
||||||
2025년의 세계 디지털 흡입기 시장 규모는 42억 달러로 평가되었습니다. 향후에 대해 IMARC Group은 2026-2034년에 CAGR 12.0%로 추이하며, 2034년까지 시장 규모가 121억 달러에 달할 것으로 예측하고 있습니다. 현재 북미가 시장을 독점하고 있으며, 2025년에는 45.8% 이상의 시장 점유율을 차지하고 있습니다. 이는 만성 호흡기 질환 관리에 대한 관심의 증가, 실시간 조정이 가능한 기술의 발전, 만성폐쇄성폐질환(COPD) 및 천식 등 만성 호흡기 질환의 유병률 증가에 따른 것입니다.
디지털 투여 흡입기(DDI)는 천식, 만성폐쇄성폐질환(COPD) 등 호흡기 질환을 앓고 있는 환자에게 약물을 투여하는 데 사용됩니다. 이 장치에는 약물의 투여 시간과 투여량을 기록할 수 있는 센서와 전자 기능이 내장되어 있습니다. 이를 통해 처방된 치료 계획의 준수를 돕고, 환자의 질병 상태와 약물의 효과를 더 깊이 이해할 수 있습니다. 사용자에게 피드백을 제공하고 흡입법 개선을 지원하기 위해 DDI에 대한 수요가 전 세계에서 증가하고 있습니다.
현재 DDI는 약물 투여의 편의성과 유효성을 높이기 위해 그 채택이 확대되고 있으며, 이는 시장 성장을 촉진하고 있습니다. 이와 더불어, 환자들 사이에서 효율적이고 효과적인 흡입 장치에 대한 수요가 증가하고 있는 것도 시장 전망을 밝게 하고 있습니다. 이에 따라 호흡기 질환에 취약한 고령층에서 DDI의 채택이 확대되면서 시장 성장을 촉진하고 있습니다. 여기에 치료의 투명성을 높이고 잠재적 효능을 향상시키는 DDI의 활용 확대가 시장 성장에 기여하고 있습니다. 또한 DDI에 인공지능(AI)을 접목하여 약물 사용 모니터링을 강화하고 환자에게 실시간 피드백을 제공하기 위해 DDI에 인공지능(AI)을 접목하는 것이 시장 성장을 촉진하고 있습니다. 또한 맞춤형 의료에 대한 관심이 높아진 것도 시장 성장을 지원하고 있습니다.
디지털 도즈 흡입기 시장 동향 및 촉진요인:
만성 호흡기 질환의 유병률 증가
전 세계에서 천식, 만성폐쇄성폐질환(COPD) 등 만성호흡기질환(CRD)의 유병률이 증가하고 있는 것이 시장 성장에 기여하고 있습니다. 또한 호흡기 질환을 관리해야 하는 사람들 사이에서 첨단 약물전달 시스템에 대한 수요가 증가하고 있습니다. 이와 더불어, DDI는 정확한 용량을 보장하고 환자와 의료진 모두에게 사용 현황에 대한 피드백을 제공하는 현대적인 솔루션을 제공함으로써 시장 전망을 밝게 하고 있습니다. 이를 통해 수집된 데이터는 치료 계획의 개별화, 복약 순응도 강화, CRD 관련 입원 감소에 기여할 수 있습니다.
실시간 조정을 위한 기술적 진보
많은 기업이 환자 치료와 만족도를 높이기 위해 DDI를 지속적으로 개선하기 위해 노력하고 있습니다. 이 제품들은 복용량 측정, 복약 순응도 모니터링, 의료진에게 데이터 전송 등의 기능을 제공합니다. 이에 따라 이러한 기능은 질병 관리의 개선을 촉진하고, 치료 계획을 실시간으로 조정할 수 있으며, 환자가 투약 스케줄을 준수할 수 있도록 함으로써 시장 전망을 밝게 하고 있습니다. 이와 더불어 DDI의 기술은 치료 효과에 매우 중요한 흡입 기술에 대해 환자에게 즉각적인 피드백을 제공할 수 있습니다. 그 결과, 이러한 발전은 중증 호흡기 질환을 앓고 있는 환자들의 호흡기 치료의 질을 향상시키고 있습니다.
만성 호흡기 질환 관리에 대한 관심 증가
만성 호흡기 질환(CRD) 관리에 대한 개인과 의료진들의 관심이 높아지면서 시장 성장에 기여하고 있습니다. 이에 따라 CRD를 보다 효율적이고 효과적으로 관리하기 위한 수요가 증가하고 있습니다. 또한 DDI는 복약 순응도를 모니터링하고 실질적인 피드백을 제공할 수 있으며, 이는 만성 호흡기 질환 관리의 광범위한 전략에서 매우 중요한 역할을 합니다. 또한 DDIs는 의료진이 환자의 복약 순응도 및 질병 진행 상황을 보다 심층적으로 파악할 수 있게 하여 적시에 개입을 촉진함으로써 환자에게 더 나은 치료 결과를 가져다 줄 수 있습니다. 또한 DDI가 더 나은 자기 관리를 촉진하므로 그 도입이 진행되고 있다는 점도 시장 성장을 촉진하고 있습니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 디지털 정량 흡입기 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 제품별
제8장 시장 내역 : 지역별
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
KSA 26.05.08The global digital dose inhaler market size was valued at USD 4.2 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 12.1 Billion by 2034, exhibiting a CAGR of 12.0% from 2026-2034. North America currently dominates the market, holding a market share of over 45.8% in 2025. This is due to the increasing focus on the management of chronic respiratory disease, technological advancements that allow real-time adjustments, and the increasing prevalence of chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma.
A digital dose inhaler (DDI) is used for delivering medication to individuals suffering from respiratory ailments like asthma or chronic obstructive pulmonary disease (COPD). It comprises built-in sensors and electronic features that can record when the medication is administered and the quantity of the dose. It assists in ensuring adherence to prescribed treatment routines and allowing for a better understanding of the disease of the patient and the effectiveness of the medication. As it provides feedback to the users and helps them to correct their technique, the demand for DDI is rising across the globe.
At present, the increasing adoption of DDIs, as they offer enhanced convenience and effectiveness in medication delivery, is bolstering the growth of the market. Besides this, the growing demand for efficient and effective inhalation devices among patients is offering a positive market outlook. In line with this, the rising adoption of DDIs among the geriatric population, as they are more prone to respiratory issues, is propelling the market growth. Apart from this, the increasing utilization of DDIs, as they make treatment more transparent and potentially more effective, is contributing to the market growth. Furthermore, the integration of artificial intelligence (AI) in DDIs to enable enhanced monitoring of medication usage and provide real-time feedback to patients is strengthening the market growth. Moreover, the increasing focus on personalized medicines among individuals is supporting the market growth.
Digital Dose Inhaler Market Trends/Drivers:
Increasing prevalence of chronic respiratory diseases
The rising prevalence of chronic respiratory diseases (CRDs), such as asthma and chronic obstructive pulmonary disease (COPD), among the masses worldwide is contributing to the market growth. In addition, there is an increase in the demand for enhanced drug delivery systems among individuals requiring management of their respiratory conditions. Apart from this, DDIs offer a modern solution by ensuring accurate dosage and providing feedback on usage to both patients and healthcare providers, which is offering a positive market outlook. In line with this, the data collected can be instrumental in personalizing treatment plans, improving adherence to medication regimes, and potentially reducing hospitalizations related to CRDs.
Technological advancements for real time adjustments
Various companies are continuously advancing their DDIs to provide enhanced care and satisfaction to patients. They offer features, such as dose counting, adherence monitoring, and data transmission, to healthcare providers. In line with this, these features promote better disease management, allow for real-time adjustments to treatment plans, and ensure that patients are effectively adhering to their medication schedules, which is offering a favorable market outlook. Apart from this, the technology in DDIs can provide immediate feedback to patients on their inhalation technique, which is crucial for the effectiveness of the treatment. As a result, these advancements are enhancing the quality of respiratory care for patients suffering from severe respiratory disorders.
Growing focus on chronic respiratory disease management
The rising focus on chronic respiratory disease (CRD) management among individuals and healthcare providers is contributing to the growth of the market. In line with this, there is an increase in the demand for more efficient and effective management of CRDs. Apart from this, DDIs can monitor medication adherence and provide actionable feedback, which plays a crucial role in the broader strategy of chronic respiratory disease management. In addition, they enable healthcare providers to have better insights into patient adherence and disease progression, facilitating timely interventions and potentially better outcomes for patients. Furthermore, the rising adoption of DDIs, as they promote better self-management, is propelling the market growth.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on type and product.
Breakup by Type:
- Branded Medication
- Generics Medication
Branded medication accounts for the majority of the market share
Breakup by Product:
- Metered Dose Inhaler
- Dry Powder Inhaler
Metered dose inhaler holds the largest share in the industry
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America leads the market, accounting for the largest digital dose inhaler market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share due to the increasing adoption of advanced respiratory devices. Additionally, the presence of well-established pharmaceutical and medical device companies is offering a positive market outlook. Apart from this, the rising focus on improving respiratory care solutions is contributing to the growth of the market. In addition, increasing incidences of respiratory disorders among individuals are propelling the growth of the market.
Competitive Landscape:
Various companies are investing in research and development (R&D) activities to create DDIs with enhanced features, such as improved dose counting, adherence monitoring, and real-time feedback mechanisms, to cater to the needs of patients and healthcare providers. Apart from this, companies are engaging in collaborations and partnerships to expand their technological capabilities and market reach. In line with this, they are providing more user-friendly and effective solutions for managing respiratory diseases. Besides this, major manufacturers are working on specialized inhaler solutions that are tailored to deliver complex biologics. Furthermore, companies are engaging in marketing and awareness campaigns to educate healthcare providers and patients about the advantages of digital dose inhalers over traditional ones.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided.
Some of the key players in the market include:
- 3M Company
- AstraZeneca plc
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals Limited
- H&T Presspart Manufacturing Ltd.
- Koninklijke Philips N.V.
- Lupin Limited
- Novartis AG
- OPKO Health Inc.
- Propeller Health (ResMed)
- Sensirion AG Switzerland
- Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report
1. What was the size of the global digital dose inhaler market in 2025?
2. What is the expected growth rate of the global digital dose inhaler market during 2026-2034?
3. What are the key factors driving the global digital dose inhaler market?
4. What has been the impact of COVID-19 on the global digital dose inhaler market?
5. What is the breakup of the global digital dose inhaler market based on the type?
6. What is the breakup of the global digital dose inhaler market based on the product?
7. What are the key regions in the global digital dose inhaler market?
8. Who are the key players/companies in the global digital dose inhaler market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Digital Dose Inhaler Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Branded Medication
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Generics Medication
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Product
- 7.1 Metered Dose Inhaler
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Dry Powder Inhaler
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 3M Company
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 AstraZeneca plc
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 GlaxoSmithKline plc
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.4 Glenmark Pharmaceuticals Limited
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 H&T Presspart Manufacturing Ltd.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.6 Koninklijke Philips N.V.
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Lupin Limited
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.8 Novartis AG
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 OPKO Health Inc.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.10 Propeller Health (ResMed)
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.11 Sensirion AG Switzerland
- 13.3.11.1 Company Overview
- 13.3.11.2 Product Portfolio
- 13.3.11.3 Financials
- 13.3.12 Teva Pharmaceutical Industries Ltd.
- 13.3.12.1 Company Overview
- 13.3.12.2 Product Portfolio
- 13.3.12.3 Financials
- 13.3.1 3M Company
